EC5026 is an inhibitor of soluble epoxide hydrolase (sEH; Ki = <0.05 nM).1 In vivo, EC5026 (10 mg/kg) increases conditioned place preference for the EC5026-paired chamber, indicating analgesia, in a rodent model of neuropathic pain. It also prevents withdrawal pain in morphine-dependent rats and increases the mechanical paw withdrawal threshold in a rat model of neuropathic pain induced by chronic constriction injury (CCI).2
1.Lee, K.S.S., Ng, J.C., Yang, J., et al.Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic painBioorg. Med. Chem.28(22)115735(2020) 2.Hammock, B.D., McReynolds, C.B., Wagner, K., et al.Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternativeJ. Med. Chem.64(4)1856-1872(2021)